Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil

Neuropsychopharmacology

Volumn 36, Issue 7, 2011, Pages 1385-1396

  Young, Jared W ^a   Kooistra, Klaas ^b   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

D1; D4; dopamine receptors; dopamine transporter; exploration; modafinil

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; MODAFINIL; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EXPLORATORY BEHAVIOR; FEMALE; GENOTYPE; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REARING; SYNAPSE; WILD TYPE;

ANIMALS; BENZAZEPINES; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; HYPERKINESIS; LINEAR MODELS; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, DOPAMINE; SEX FACTORS;

EID: 79955993476     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.23     Document Type: Article

References (66)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH et al (1996). A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93: 1945-1949. (Pubitemid 26079860)
2. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL (2010). Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology (Berl) 210: 439-448.
3. Bay-Richter C, O'Tuathaigh CM, O'Sullivan G, Heery DM, Waddington JL, Moran PM (2009). Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. Int J Neuropsychopharmacol 12: 403-414.
4. Chang WL, Geyer MA, Buell MR, Weber M, Swerdlow NR (2010). The effects of pramipexole on prepulse inhibition and locomotor activity in C57bl/6j mice. Behav Pharmacol 21: 135-143.
5. Crawford CA, Drago J, Watson JB, Levine MS (1997). Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1a-deficient mouse. NeuroReport 8: 2523-2527. (Pubitemid 27308454)
6. De Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S (2001). Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. NeuroReport 12: 3533-3537. (Pubitemid 33065493)
7. Dickinson SD, Sabeti J, Larson GA, Giardina K, Rubinstein M, Kelly MA et al (1999). Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 72: 148-156. (Pubitemid 29013888)
8. Doherty JM, Masten VL, Powell SB, Ralph RJ, Klamer D, Low MJ et al (2008). Contributions of Dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology 33: 2648-2656.
9. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE et al (1994). Altered striatal function in a mutant mouse lacking D1a dopamine receptors. Proc Natl Acad Sci USA 91: 12564-12568.
10. Dulawa SC, Grandy DK, Low MJ, Paulus MP, Geyer MA (1999). dopamine d4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19: 9550-9556. (Pubitemid 30228106)
11. Eagle DM, Tufft MR, Goodchild HL, Robbins TW (2007). Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psycho-pharmacology (Berl) 192: 193-206. (Pubitemid 46669203)
12. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D et al (1996). Dopamine D4 receptor (d4dr) exon iii polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12: 78-80. (Pubitemid 26011323)
13. Elliot EE, Sibley DR, Katz JL (2003). Locomotor and discriminative- stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology (Berl) 169: 161-168. (Pubitemid 37129967)
14. Farrow TF, Hunter MD, Haque R, Spence SA (2006). Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial. Br J Psychiatry 189: 461-462. (Pubitemid 44683181)
15. Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C (2000). Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci 12: 19-26. (Pubitemid 30068407)
16. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K (1997). The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuro-Report 8: 2883-2887. (Pubitemid 27394812)
17. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1998). The effects of modafinil on striatal, pallidal and nigral gaba and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal gaba transmission. Neurosci Lett 253: 135-138. (Pubitemid 28430641)
18. Ferraro L, Antonelli T, Tanganelli S, O'Connor WT, Perez de la Mora M, Mendez-Franco J et al (1999). The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local gabaa receptor blockade. Neuropsychopharmacology 20: 346-356. (Pubitemid 29099765)
19. Flicker C, Geyer MA (1982). The hippocampus as a possible site of action for increased locomotion during intracerebral infusions of norepinephrine. Behav Neural Biol 34: 421-426. (Pubitemid 12062126)
20. Geyer MA, Russo PV, Masten VL (1986). Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25: 277-288. (Pubitemid 16040937)
21. Greenhill LL (2006). The science of stimulant abuse. Pediatr Ann 35: 552-556. (Pubitemid 44265546)
22. Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, Geyer MA et al (2010). Isolation rearing-induced deficits in contextual fear learning do not require crf(2) receptors. Behav Brain Res 209: 80-84.
23. Guo G, Tong Y, Xie CW, Lange LA (2007). Dopamine transporter, gender, and number of sexual partners among young adults. Eur J Hum Genet 15: 279-287.
24. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA et al (2009). 5-Ht(2a) and 5-Ht(2c) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34: 1958-1967.
25. Harrod SB, Mactutus CF, Bennett K, Hasselrot U, Wu G, Welch M et al (2004). Sex differences and repeated intravenous nicotine: behavioral sensitization and dopamine receptors. Pharmacol Biochem Behav 78: 581-592. (Pubitemid 38901025)
26. Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR et al (2001). Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 115: 1129-1144. (Pubitemid 32906651)
27. Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ et al (1999). Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci 2: 649-655. (Pubitemid 30491216)
28. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G et al (1998). Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18: 3470-3479. (Pubitemid 28186038)
29. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L et al (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569.
30. McDougall SA, Reichel CM, Cyr MC, Karper PE, Nazarian A, Crawford CA (2005). Importance of D(1) receptors for associative components of amphetamine-induced behavioral sensitization and conditioned activity: a study using D(1) receptor knockout mice. Psychopharmacology (Berl) 183: 20-30. (Pubitemid 41484179)
31. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Croke DT et al (2003). Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioral topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28: 86-99.
32. Mignot E, Nishino S, Guilleminault C, Dement WC (1994). Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17: 436-437. (Pubitemid 24271517)
33. Miner LL, Drago J, Chamberlain PM, Donovan D, Uhl GR (1995). Retained cocaine conditioned place preference in d1 receptor deficient mice. NeuroReport 6: 2314-2316. (Pubitemid 26010067)
34. Minzenberg MJ, Carter CS (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsycho-pharmacology 33: 1477-1502. (Pubitemid 351684703)
35. Munafo MR, Yalcin B, Willis-Owen SA, Flint J (2008). Association of the dopamine D4 receptor (drd4) gene and approach-related personality traits: meta-analysis and new data. Biol Psychiatry 63: 197-206. (Pubitemid 350299323)
36. Paulus MP, Geyer MA (1991). A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats. Prog Neuropsychopharma-col Biol Psychiatry 15: 903-919.
37. Paulus MP, Geyer MA (1993). Three independent factors characterize spontaneous rat motor activity. Behav Brain Res 53: 11-20. (Pubitemid 23074026)
38. Perry W, Minassian A, Henry B, Kincaid M, Young JW, Geyer MA (2010). Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res 178: 84-91.
39. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ et al (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072-1080.
40. Powell SB, Young JW, Ong JC, Caron MG, Geyer MA (2008). Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 19: 562-565.
41. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y (2008). Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 28: 8462-8469.
42. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002). Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22: 9604-9611. (Pubitemid 35356202)
43. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006). Differential contributions of dopamine D(1), D(2), and D(3) receptors to Mdma-induced effects on loco-motor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358. (Pubitemid 44607051)
44. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G et al (1997). Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90: 991-1001. (Pubitemid 27408513)
45. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS et al (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20: 8620-8628.
46. Simon P, Hemet C, Ramassamy C, Costentin J (1995). Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 5: 509-514.
47. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005). Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychophar-macology (Berl) 182: 186-193. (Pubitemid 41400876)
48. Tanganelli S, Ferraro L, Bianchi C, Fuxe K (1994). 6-Hydroxy-dopamine treatment counteracts the reduction of cortical gaba release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci Lett 171: 201-204. (Pubitemid 24142124)
49. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C (1992). Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxy-tryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 345: 461-465.
50. Tsuchimine S, Yasui-Furukori N, Kaneda A, Saito M, Sugawara N, Kaneko S (2009). Minor genetic variants of the dopamine D4 receptor (Drd4) polymorphism are associated with novelty seeking in healthy Japanese subjects. Prog Neuropsychopharma-col Biol Psychiatry 33: 1232-1235.
51. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004). Modafinil improves cognition and atten-tional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29: 1363-1373. (Pubitemid 38780659)
52. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165: 260-269. (Pubitemid 36197601)
53. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
54. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001). Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21: 1787-1794. (Pubitemid 32184295)
55. Xu M, Guo Y, Vorhees CV, Zhang J (2000). Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res 852: 198-207. (Pubitemid 30017751)
56. Young JW (2009). Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness. J Neurosci 29: 2663-2665.
57. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C et al (2007a). Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsycho-pharmacol 17: 145-155. (Pubitemid 44802833)
58. Young JW, Geyer MA (2010). Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry 67: 784-787.
59. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA (2010a). Gbr 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) 208: 443-454.
60. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA (2010b). The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 96: 7-15.
61. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA (2010c). The mania-ike exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 96: 7-15.
62. Young JW, Light GA, Marston HM, Sharp R, Geyer MA (2009a). The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One 4: e4227.
63. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W (2007b). A reverse-translational approach to bipolar disorder: rodent and human studies in the behavioral pattern monitor. Neurosci Biobehav Rev 31: 882-896. (Pubitemid 47285352)
64. Young JW, Powell SB, Geyer MA, Jeste DV, Risbrough VB (2010d). The mouse attentional set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci 10: 243-251.
65. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009b). Using the matrics to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122: 150-202.
66. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V et al (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.